Gilead’s $11.5B Bet: What Two Companies Saw in One Week
Gilead and UCB deployed $3B+ on similar autoimmune drugs within days. What this pharmaceutical investment convergence signals for institutional investors tracking women’s health.
Healthcare Innovation
The Future of Healthcare Innovation
7 Min Read How aging populations, rising costs, and institutional inertia quietly reshaped medicine into one of the largest sectors